ArticleScientific reports2022
Optimization of intraperitoneal aerosolized drug delivery using computational fluid dynamics (CFD) modeling.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Computational approaches in bioprinting processes.Nature reviews bioengineering · 2026Article
- Effects of multi-electrode electrostatic precipitation during intraperitoneal aerosolized drug delivery: Insights from a large animal model.Bioengineering & translational medicine · 2026Article
- Advancements in nebulizers for pressurized intraperitoneal aerosol chemotherapy (PIPAC).Pleura and peritoneum · 2025Review
- Physiological Considerations and Delivery Strategies for Targeting Tumors Through Intraperitoneal Delivery.Pharmaceutical research · 2025Review
- Subject-specific modeling framework for particle deposition using computational fluid dynamics.Journal of aerosol science · 2025Article
- Increasing Nebulizer Spray Efficiency Using a Baffle with a Conical Surface: A Computational Fluid Dynamics Analysis.Bioengineering (Basel, Switzerland) · 2025Article
- A novel nebulized drug delivery system based on an innovative high-pressure peristaltic pump availably applied to pressurized intraperitoneal aerosol chemotherapy.Journal of gastrointestinal oncology · 2025Article
- Article
- Performance of different nebulizers in clinical use for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).PloS one · 2024Article
- Computational Fluid Dynamics (CFD) Model for Analysing the Role of Shear Stress in Angiogenesis in Rheumatoid Arthritis.International journal of molecular sciences · 2023Article
- Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer.Frontiers in oncology · 2023Review
- Theoretical analysis for the fluctuation in the electric parameters of the electroporated cells before and during the electrofusion.Medical & biological engineering & computing · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraperitoneal (IP) aerosolized anticancer drug delivery was recently introduced in the treatment of patients with peritoneal metastases. However, little is known on the effect of treatment parameters on the spatial distribution of the aerosol droplets in the peritoneal cavity. Here, computational fluid dynamics (CFD) modeling was used in conjunction with experimental validation in order to investigate the effect of droplet size, liquid flow rate and viscosity, and the addition of an electrostatic field on the homogeneity of IP aerosol. We found that spatial distribution is optimal with small droplet sizes (1-5 µm). Using the current clinically used technology (droplet size of 30 µm), the optimal spatial distribution of aerosol is obtained with a liquid flow rate of 0.6 mL s
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.